Earlier this month, three abstracts co-authored by TOI physicians were accepted to ASCO. TOI Physicians are committed to advancing cancer research and contributing to the development of cutting-edge cancer treatments. Both clinical trials included in these abstracts have the potential to positively impact patient lives.
Dr. Michael Chung contributed to a Phase 3 clinical trial treating diffuse large B-cell lymphoma. This drug is a possible treatment for patients who have exhausted many other treatment options and are ineligible for an autologous stem cell transplant.
Dr. Merrill Shum participated in a trial for a drug that targets a new mutation in Non-Small Cell Lung Cancer patients. The trial is expanding to 200+ patient participants in 20 counties, and TOI will serve as one of the host sites.
With more than 130 clinical trials offered at TOI, we bring leading-edge therapies to our patients while contributing to the advancement of cancer treatment for patients around the word. Congratulations to Drs. Chung and Shum on this accomplishment!